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Recurrencea b s t r a c t
Introduction and objectives: Recurrence rates for patients presenting with non-muscle invasive bladder
carcinoma (NMIBC) can be as high as 60% during the first year after a transurethral resection of bladder
tumor (TURBT). Currently, an immediate postoperative instillation of chemotherapy (IPOIC) is recom-
mended for the prevention of recurrences in patients with low to intermediate risk disease. Although
in real clinical practice this specific instillation of chemotherapy has many difficulties to be standardized,
including its contraindications (suspected or confirmed bladder perforation, wide or extensive resection
and, continuous bladder irrigation requirement), which will only make it feasible for around 30% of
patients.
We propose in this controlled study, to administer an immediate neoadjuvant instillation of
chemotherapy (INAIC), which can be applied technically to all patients, no matter the surgical outcomes
and compare it with a control group. We expect to find a reduction in the recurrence rate in the exper-
imental group of at least 15%.
Methods: We designed a phase IV, randomized, controlled, open label clinical trial. Main inclusion criteria
are: patients with a clinical diagnosis of localized, papillary-type bladder cancer (suspected low to inter-
mediate risk) with a disease-free interval of at least 6 months. Eligible patients will be allocated into
group A (INAIC plus TURBT) or group B (TURBT) using a computer-generated block randomization
sequence/ratio 1:1. Time to recurrence of both groups will be analyzed and compared using Kaplan-
Meier estimates, log-rank tests and, Cox-regression. Univariate and multivariate analyzes will be per-
formed to determine factors which influence recurrence. The study has received the approval of the
Ethics Committee for Drug Research (CEIm) of La Paz University Hospital and the Spanish Agency for
Medicines and Health Products.
 2020 The Author(s). Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
1.1. Introduction
Bladder carcinoma (BCa) is the seventh most common cancer in
the male population and the eleventh most common in women
worldwide. The age-standardized incidence rate is 9.0 for men
and 2.2 for women [1,2]. In the European Union, the age-
standardized incidence rate is 19.1 in men and 4.0 in women [1,2].Histologically, 90% of bladder tumors are of urothelial origin, 5%
are squamous cell carcinomas, and less than 2% are adenocarcino-
mas or other variants [3].
From all urothelial BCa at presentation, approximately 70% are
non-muscle invasive (NMIBC), of these, 70% present in stage Ta,
20% as T1, and 10% as CIS (carcinoma in situ) [4]. These tumors
are grouped into the definition of NMIBC, because they can be trea-
ted with transurethral resection of bladder tumor (TURBT) and/or
intravesical instillations.
To facilitate treatment recommendations, it is important to cat-
egorize patients according to risk groups. The standard classifica-
tion, which is recommended by the European Association of
Urology (EAU) guidelines on bladder cancer is based on available
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tables, and it divides patients into three groups (Table 1).
Depending on the stage and grade, the number and size of
tumors, the probability of recurrence of NMIBC can be as high as
60% in the first year and 80% at 5 years after diagnosis. Low-
grade Ta tumors have a 50% to 70% recurrence rate, and progress
in approximately 5% of cases. In contrast to high-grade T1 tumors
that can recur in up to 80%, and progress in up to 50% of patients
within 3 years [5–7].
The EAU guidelines recommend the administration of an imme-
diate post-operative instillation of chemotherapy (IPOIC) after
TURBT in patients with bladder tumors that are presumed to be
NMIBC of low or intermediate risk, that have a low recurrence rate
(less than one at one year) and an expected EORTC (European
Organization of Research and Treatment of Cancer) recurrence
score < 5 (Level of evidence: 1 a. Grade of recommendation: A)
[6]. In the United States, the same practice is recommended by
the American Urological Association (AUA) guidelines [8].
This recommendation is based on the results of four large
meta-analyzes which have consistently shown that IPOIC after
TURB reduces recurrences compared to TURBT alone [9–12]. On
the other hand, contraindications of an IPOIC include: a con-
firmed or suspected intraperitoneal or extraperitoneal bladder
perforation, a wide or extensive resection, or the requirement
of continuous intravesical irrigation due to hematuria [6]. Ideally,
an IPOIC should be administered within the first 24 hours after
surgery (preferably within 2 hours) and it should last for 1–2
hours [6].
Although no comparative studies have been performed
between different chemotherapeutic agents, mitomycin C (MMC),
epirubicin, and pirarubicin have shown similar beneficial effects
[9–12]. Moreover, in addition to an IPOIC, the benefit of continuous
irrigation with normal saline has shown efficacy in two meta-
analyzes [13,14].
The rational explanation for the effectiveness of an IPOIC is
based on its antitumor effect in the resection site, in destroying
floating cells that can implant further on, and in destroying small
tumors that have been overlooked [15,16].
Despite the previous growing evidence that an IPOIC reduces
recurrences of NMIBC, many urologists worldwide still do not
apply it in their daily practice, due to the fact that in a considerable
number of patients (approximately 2 out of 3), the presence of
post-operative hematuria or the extent and/or depth of the resec-
tion contraindicates this practice [17–19]. So technically, this prac-
tice can only be performed in approximately 30% of patients who
undergo a TURBT.
Studies which have analyzed the use of an IPOIC have shown
that in the United States, only 0.33–45% of patients who under-
went a TURBT for suspected NMIBC received it, and that around
66% of urologists do not use it [20–22]. Meanwhile, in 5 EuropeanTable 1
Non-muscle invasive bladder cancer risk group stratification (adapted from Babjuk M,




















PUNLMP: Papillary urothelial neoplasm of low malignant potential; LG: low grade
(includes G1 and some forms of G2); G: high grade (includes some G2 and all G3).
22countries (Germany, Spain, France, Italy, United Kingdom), only
56.7% of patients received it, and 28% of urologists do not use it
[23]. In the previously mentioned studies, authors describe possi-
ble justifications for not performing this routine practice, such
as: problems with low reimbursement, difficulties in preparing
chemotherapy drugs and delivering them to the operating room
on time, lack of organization, insufficient training of the nursing
staff in the use of chemotherapy, among others [20–23]. Further-
more, the lack of scientific evidence of its usefulness in intermedi-
ate and high-risk tumors may contribute to the non-compliance of
this step in the treatment of NMIBC.
The role of an immediate neoadjuvant instillation of
chemotherapy (INAIC) has not been studied other than in a
prospective, randomized clinical trial using an electromotive drug
administration device (EMDA) with MMC [24]. In this study pub-
lished by Di Stasi in 2011, it was found that patients who received
neoadjuvant MMC with EMDA experienced a longer disease-free
interval compared to TURBT alone, and TURB plus IPOIC: 51months
versus 16 months versus 12 months (P < 0.001) [24]. Although no
data on progression or disease specific survival were included,
these findings are promising for the use of a neoadjuvant instilla-
tion of chemotherapy.
At the beginning, this clinical trial was intended to use only Mit-
omycin C as the only chemotherapeutic agent, but due to the stock
break and shortage in Spain at the end of 2019, we have decided to
propose the use of other drugs with the same indication and evi-
dence that justifies its use in this disease (Epirubicin, Adriamycin,
Cisplatin, Gemcitabine, Docetaxel). All the drugs mentioned before
are authorized for use in intravesical instillations for the preven-
tion of recurrences of urothelial bladder carcinoma, just like Mito-
mycin C, and none has shown superiority over another in clinical
trials [6,25–29]. Every effort will be made to avoid excessive diver-
sification between drugs and use Mitomycin C, Gemcitabine or
Epirubicin whenever possible.
In this study we propose to carry out an intravesical instillation
of chemotherapy in a neoadjuvant way (INAIC), that is, immedi-
ately before TURBT. If it were effective in prolonging disease-free
intervals and reducing the recurrence rate, its use in urology
departments would be easily adopted and it could benefit patients
regardless of the extension and depth of the TURBT.
In any case, the administration, or not, of neoadjuvant
chemotherapy will not influence the subsequent surgical treat-
ment and the procedures in the follow-up of the patient in this
clinical trial, which will be carried out according to the usual clin-
ical practice, based on the risk groups.1.2. Rationale
If there is a considerable number of patients who will not be
able to receive an IPOIC due to the previous mentioned contraindi-
cations and lack of use in clinical practice by urologists worldwide
due to its complexity, it will not help to prolong their disease-free
intervals. In this scenario, we should come out with a novel strat-
egy, in which potentially all patients can benefit from
chemotherapy.
In the light of this conclusion, we decide to create a randomized,
open label, controlled trail, comparing the use of INAIC before
TURB and compare the disease-free intervals with a control group.
A protocol or results from a similar study have not been published
in the medical literature so far.
Based on the evidence, we hypothesize that neoadjuvant
chemotherapy may act on neoformative foci not visible due to
their size during TURBT and may also reduce the possibility of
tumor cell implantation by weakening floating tumor cells.
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2.1. Study design: clinical trial, phase IV, randomized, open label,
controlled
2.1.1. Study arms
- Experimental: A Intervention: patients will receive an intraves-
ical instillation of neoadjuvant chemotherapy (40 mg of MMC
dissolved in 40 ml of normal saline) and immediately after-
wards, TURBT will be performed.
- Control group: B Intervention: TURBT
2.1.2. Follow-up
Patients in both arms will be followed-up according to standard
clinical practice according to the guidelines established in our ser-
vice: first cystoscopy and urine cytology at 3 months. Subse-
quently, the follow-up will be done according to the
recommendations of the EAU guidelines [6].
We define early recurrence as a reappearance of the bladder
tumor in the first 12 months after resection.
The subsequent treatment of NMIBC will be carried out accord-
ing to the guidelines established in our service, regardless of the
treatment group to which it has been assigned. Thus,
intermediate-risk patients will be given intravesical prophylaxis
treatment with MMC at a schedule of 40 mg weekly for the first
4 weeks (starting 2 weeks after TURB) followed by a monthly
administration of 40 mg for 11 months.
2.1.3. Place of realization
We have started the study at the La Paz University Hospital in
Madrid. Currently other centers who collaborate with the Club
Urológico Español de Tratamiento Oncológico (CUETO) in Spain
have decided to collaborate and are under the process of becoming
approved enrollment centers.
2.2. Eligibility criteria
Inclusion and exclusion criteria are summarized in Table 2:
2.3. Interventions
Patients randomized in the intervention group (Group A) will
receive an INAIC through a 16Fr Foley catheter for 15 minutes right
after the induction of anesthesia and prior to TURBT. The preferred
agent for INAIC will be MMC 40 mg. In case that MMC is notTable 2
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Both sexes,  18 years old, clinical
and/or imaging evidence of
localized papillary-type BCa with
indication for TURBT.
Solid-looking or muscle-invasive
tumors on cystoscopy and/or
preoperative imaging tests
History of NMIBC: Ta / T1, G1-G3,
without CIS, with disease-free
interval > 6 months
Allergy to intravesical administered
chemotherapeutic agents
Karnofsky scale score > 70%. Pregnancy
Agreement of the patient to
participate, signed informed
consent.
Severe urethral stricture/stenosis or
inability to catheterize the bladder
for any other reason prior to TURBT
Patients in whom follow-up will not
be possible for any reason.
Final diagnosis different from that of
Ta-T1 tumors
BCa: Bladder carcinoma; TURBT: transurethral bladder resection of bladder tumor;
CIS: carcinoma in situ.
23available at the pharmacy, other approved agents are Epirrubicin,
Gemcitabine, Adriamycin, Cisplatin and, Docetaxel.
2.4. Aims and objectives
Primary Objective:
- Evaluation of the early recurrence rate (<12 months) of NMIBC
comparing both study arms.
Secondary Objectives:
- Evaluation of toxicity, adverse events and complications attri-
butable to intravesical instillation of chemotherapy prior to
TURBT.
- Determine the late recurrence rate (12–60 months).
- Compare the recurrence-free interval between both groups.
- Determine clinical and demographic variables that could influ-
ence clinical response.
- Determine differences in rate of recurrence, adverse effects and
other variables between patients in the intervention group who
have received different drugs.
2.5. Sample size
The sample size is calculated to find a reduction of 15% in group
A (INAIC + TURB) over group B (TURB alone), assuming that the
recurrence rate in group B is 60%. A total of 120 patients will be
required in each group, with a probability of 80% and a 5% type 1
error.
2.6. Allocation
Patients will be assigned to 1 of the 2 groups using a computer-
generated block randomization sequence. Participants will be
intentionally placed in equal numbers to each group (A or B)
according to a block of 4 (randomization ratio 1: 1 in each block).
The randomization process will take place when the exact day and
time of surgery is known (approximately 1 to 2 weeks prior to
surgery).
2.7. Data collection
At the time of registration, each patient will be assigned a
Patient Number. This Patient Number will be noted on the elec-
tronic medical record and in the database. The researcher will be
responsible for keeping adequate information about each patient
so that health authorities can have access to such information if
necessary. These records must be kept confidential during the per-
iod of time legally ordered by current regulations.
The documentation related to the study (protocol, database,
signed informed consents, authorizations, etc) will be stored in
the Urology Department at La Paz University Hospital in a safe
place and easily accessible by the research team. All information
contained in clinical, histological, biochemical, and molecular
reports, observations, or other activities is necessary for the recon-
struction and evaluation of the study.
2.8. Timeline
The study started on May 2018, after obtaining the approval of
the study by the Ethics Committee for Drug Research (CEIm) of the
Hospital Universitario La Paz and the Spanish Agency for Medicines
and Health Products (AEMPS).
The study is intended to be carried out according to the follow-
ing work plan:
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- Duration of the follow-up period for each patient: 5 years.
- Analysis of the results and preparation of the final report:
3 months.
- End of study: last scheduled visit of the last patient in the study.
2.9. Quality control
The study will be monitored by a monitor, who will draw up a
suitable monitoring plan for the study. Regular visits and phone
calls will be made to investigators. The monitor should evaluate
the study procedures and discuss any problems with the investiga-
tor. During the course of the study, audit visits may be carried out
at the participating centers.2.10. Data analysis plan
The qualitative variables will be analyzed in 2x2 tables, they
will be compared using the v2 (Chi-square) test.
Main variable: The time to the recurrence of NIMCV will be ana-
lyzed between both groups using Kaplan-Meier estimates, log-rank
test and Cox regression. The recurrence rate per year will be
defined as the total number of recurrences confirmed by patholog-
ical analysis divided by the number of years of follow-up. The
recurrence rate per year between the two groups will be compared
by Fisher’s exact test or Student’s t test.
Secondary variables: Univariate and multivariate analyzes will
be performed to determine the factors that affect recurrence.
Two homogeneous groups will be generated (Group A and B)
avoiding conformational biases (selection bias, attrition bias),
through statistical analysis by intention to treat/stratified blocks,
considering risk factors for recurrence (low and intermediate)
based on in the latest reviews of scientific literature: sex, age,
smoking history, American Society of Anesthesiologists (ASA) clas-
sification system status, Charlson Comorbidity Index (CCI), tumor
size, number of tumors, urinary cytology, history of previous
NMIBC, history of previous intravesical chemotherapy treatment,
adverse effects, surgical complications.
In order to minimize information biases (detection, confusion),
multivariate analysis techniques will be used. In all the analyzes, a
significance level (p) will be established at values below 0.05, that
is, a 95% confidence interval.3. Ethics and dissemination
The treatment, communication and transfer of the personal
data of all the participating subjects will comply with the provi-
sions of the Spanish Organic Law 15/1999, of December 13, on
the protection of personal data.
The study will be carried out in accordance with the recommen-
dations for clinical studies and drug evaluation in humans, which
appear in the latest version of the Declaration of Helsinki (For-
taleza, Brazil October 2013, Annex 3), revised in successive world
assemblies, and the current Spanish Legislation on Clinical Studies
(RD 1090/2015, of December 4, which regulates clinical trials with
drugs).4. Trial registration number and approval
This trial was approved by the Spanish agency of Medicines and
Medical Devices (AEMPS) with the trial number: EudraCT 2017–
004070-34. First approved: January 29th 2018. Last protocol ver-
sion: 3.0 May 12th 2020.24Title of the clinical trial in Spanish: ‘‘Instilación vesical de
qumioterapia previa a la resección transuretral de vejiga en el tra-
tamiento del cáncer de vejiga”.
Link to the registration (must be publicly accessible): https://
reec.aemps.es/reec/public/list.html
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Appendix A. Trail registration data:Data category InformationPrimary registry and trial
identification numberEudraCT 2017–004070-34Protocol code PRECAVE
Date of authorization in
primary registry
January 29th 2018Sources of monetary of
financial supportSupported by grants from the
Foundation for Research in
Urology (Spanish Urological
Association) and from the
Community of Madrid
(Immunothercan-CM(B2017/BM
D3733)Sponsor Dr. Luis Martínez-Piñeiro Lorenzo
– Urology Department, La Paz
University Hospital, Madrid, SpainContact for public
queriesluis.mpineiro@salud.madrid.org
diego.carrion@salud.madrid.org
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controlledPublic title Instilación vesical de qumioterapia
previa a la resección transuretral
de vejiga en el tratamiento del
cáncer de vejigaScientific title Ensayo clínico aleatorizado,
abierto para evaluar la instilación
vesical de quimioterapia
neoadyuvante a la resección
transuretral de vejiga para la
prevención de recurrencia del
carcinoma urotelial no músculo
invasivoCountries of recruitment Spain
Interventions Group A: instilation of intravesical
chemotherapy immediately prior
to TURBT. Group B: controlDate of first patient
enrolledMay 29th 2018Recruitment status Patient enrollment ongoing
Key inclusion criteria Age  18 years, any gender
Localized, papillary-type, bladder
carcinoma
Disease free interval > 6 months




Any reason for not being able to
catheterize the bladder prior to
surgeryPrimary outcome Evaluate early recurrence rate
(<12 months)Secondary outcomes Evaluate toxicity, adverse events
and complications Determine late
recurrence rate (12–60)
Determine the late recurrence rate
(12–60 months) Compare the
recurrence-free interval
Determine clinical and
demographic variables that could
influence clinical response
Determine differences in rate of
recurrence, adverse effects and
other variables between patients
in the intervention group who
have received different drugsReferences
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